Laboratory Corporation of America Holdings (NYSE:LH) – Stock analysts at Jefferies Group lifted their Q3 2017 EPS estimates for shares of Laboratory Corporation of America Holdings in a research note issued to investors on Tuesday. Jefferies Group analyst B. Tanquilut now forecasts that the medical research company will post earnings of $2.44 per share for the quarter, up from their previous forecast of $2.43. Jefferies Group has a “Hold” rating and a $170.00 price objective on the stock. Jefferies Group also issued estimates for Laboratory Corporation of America Holdings’ Q4 2017 earnings at $2.37 EPS, FY2017 earnings at $9.51 EPS and FY2018 earnings at $10.60 EPS.

A number of other equities research analysts have also issued reports on LH. ValuEngine raised shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday. Barclays PLC upped their target price on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. BidaskClub lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Finally, Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $164.00.

WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/14/q3-2017-eps-estimates-for-laboratory-corporation-of-america-holdings-lh-boosted-by-jefferies-group.html.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 155.21 on Thursday. Laboratory Corporation of America Holdings has a 12-month low of $119.51 and a 12-month high of $164.22. The company has a market cap of $15.80 billion, a price-to-earnings ratio of 21.74 and a beta of 0.94. The stock has a 50 day moving average of $157.04 and a 200 day moving average of $147.47.

Laboratory Corporation of America Holdings (NYSE:LH) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.47 billion. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The business’s revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the business earned $2.36 EPS.

In other Laboratory Corporation of America Holdings news, Director R Sanders Williams sold 3,100 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the transaction, the director now owns 10,073 shares of the company’s stock, valued at $1,580,252.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Lisa J. Uthgenannt sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $160.00, for a total transaction of $800,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 222,968 shares of company stock worth $34,980,922. Corporate insiders own 0.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of LH. Profund Advisors LLC lifted its position in Laboratory Corporation of America Holdings by 11.5% in the first quarter. Profund Advisors LLC now owns 4,099 shares of the medical research company’s stock valued at $588,000 after buying an additional 423 shares during the last quarter. Commerzbank Aktiengesellschaft FI acquired a new position in Laboratory Corporation of America Holdings in the first quarter valued at about $374,000. Swiss National Bank lifted its position in Laboratory Corporation of America Holdings by 23.2% in the first quarter. Swiss National Bank now owns 451,775 shares of the medical research company’s stock valued at $64,816,000 after buying an additional 85,100 shares during the last quarter. World Asset Management Inc lifted its position in Laboratory Corporation of America Holdings by 14.0% in the first quarter. World Asset Management Inc now owns 10,904 shares of the medical research company’s stock valued at $1,564,000 after buying an additional 1,339 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in Laboratory Corporation of America Holdings by 1.7% in the first quarter. UBS Asset Management Americas Inc. now owns 905,278 shares of the medical research company’s stock valued at $129,880,000 after buying an additional 15,137 shares during the last quarter. 93.21% of the stock is currently owned by institutional investors.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.